Showing results (1-10 of 133) with videos related to
Sort By:
Pageof 14
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 30, 2013
Stressing the development of small molecules targeting HSP90Len Neckers, Jane B TrepelCurrent Opinion in Investigational Drugs (London, England : 2000)|December 15, 2010
STA-9090, a small-molecule Hsp90 inhibitor for the potential treatment of cancerYisong Wang, Jane B Trepel, Leonard M Neckers, et al.Nature Reviews. Molecular Cell Biology|July 31, 2023
Structural and functional complexity of HSP90 in cellular homeostasis and diseaseGabriela Chiosis, Chander S Digwal, Jane B Trepel, et al.Current Opinion in Oncology|March 18, 2017
Immunotherapy: a new treatment paradigm in bladder cancerNicole N Davarpanah, Akira Yuno, Jane B Trepel, et al.Expert Opinion on Drug Metabolism & Toxicology|July 27, 2006
Assays for pharmacodynamic analysis of histone deacetylase inhibitorsEun Joo Chung, Min-Jung Lee, Sunmin Lee, et al.Leukemia Research|July 20, 2002
Anticancer-drug-induced apoptotic cell death in leukemia cells is associated with proteolysis of beta-cateninSang Gu Hwang, Hyung Chul Lee, Jane B Trepel, et al.Leukemia Research|October 24, 2007
KIT regulates tyrosine phosphorylation and nuclear localization of beta-catenin in mast cell leukemiaTomohiro Kajiguchi, Sunmin Lee, Min-Jung Lee, et al.Current Opinion in Oncology|October 9, 2008
Histone deacetylase inhibitors in cancer therapyMin-Jung Lee, Yeong Sang Kim, Shivaani Kummar, et al.Cell Stress & Chaperones|February 3, 2018
Methods to validate Hsp90 inhibitor specificity, to identify off-target effects, and to rethink approaches for further clinical developmentLen Neckers, Brian Blagg, Timothy Haystead, et al.Cell Stress & Chaperones|March 15, 2002
Hsp90, not Grp94, regulates the intracellular trafficking and stability of nascent ErbB2Wanping Xu, Edward G Mimnaugh, Jung-Sik Kim, et al.Pageof 14